FIELD: medicine.
SUBSTANCE: invention concerns a peptide with the sequence Abu-Ser-Ser-Val-Lys-Val-Ser-Abu (Abu-α-aminobutyric acid), corresponding to the conservative site of the VH domain of the human immunoglobulin heavy chain, intended for the treatment of multiple sclerosis in humans.
EFFECT: invention provides the suppression of proliferative activity of lymphocytes.
1 cl, 1 ex, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ACTH-LIKE PEPTIDE WITH IMMUNOSUPRESSOR FUNCTION | 2017 |
|
RU2681317C1 |
| LIPOSOMES CONTAINING OLIGOPEPTIDES - FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING MULTIPLE SCLEROSIS | 2009 |
|
RU2448685C2 |
| PEPTIDE | 2014 |
|
RU2675479C2 |
| METHOD OF OBTAINING ABM-TGIRIS-ABU IMMUNOSUPPRESSOR PEPTIDE LABALED BY GD ION | 2017 |
|
RU2681318C1 |
| LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD FOR MULTIPLE SCLEROSIS TREATMENT | 2013 |
|
RU2639497C2 |
| INJECTABLE DOSAGE FORM OF OLIGOPEPTIDE PREPARATION FOR TREATING MULTIPLE SCLEROSIS AND METHOD FOR PRODUCING IT | 2010 |
|
RU2561582C2 |
| RELEASE AND IDENTIFICATION OF T-CELLS | 2003 |
|
RU2327487C2 |
| SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF USING IN IMMUNE DISEASES | 2014 |
|
RU2707812C1 |
| GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
| PEPTIDE | 2014 |
|
RU2667428C2 |
